HNF4A and gastric cancer: CCL15 could be regarded as a biomarker to guide therapy in GC patients with a high expression of P1-HNF4A, and pharmaceutical intervention of the CCL15 signaling pathway may provide a promising strategy to improve the prognoses of GC patients.